Strategic Partnership
Gilead Sciences and Arcus Biosciences Complete Closing of Their 10-Year Partnership to Co-Develop and Co-Commercialize Next-Generation Cancer Immunotherapies
Gilead Sciences
PR-M07-20-NI-021Jul 15, 2020
Partnership
Gilead Sciences and Arcus Biosciences Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies
Gilead Sciences
PR-M05-20-NI-041May 28, 2020
Phase I Trial
Arcus Biosciences Announces Initiation of Phase 1 Trial for AB154, its Anti-TIGIT Antibody
Arcus Biosciences
PR-M08-18-NI-012Aug 03, 2018
Arcus Biosciences and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Lead Programs in Triple-Combination Studies
Infinity Pharmaceuticals
PA4053Jun 27, 2018